We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+15.42%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$154M
Cap. Flow
+$142M
Cap. Flow %
26.23%
Top 10 Hldgs %
64.51%
Holding
60
New
22
Increased
12
Reduced
3
Closed
21

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$37.3M
2
MRK icon
Merck
MRK
+$20.1M
3
VTRS icon
Viatris
VTRS
+$18M
4
ABLX
Ablynx NV
ABLX
+$14.4M
5
SHPG
Shire pic
SHPG
+$13.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$20.3M
2
GSK icon
GSK
GSK
+$14.5M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$12.9M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$10.7M
5
AKAO
Achaogen Inc
AKAO
+$9.21M

Sector Composition

Rank Sector Weight
1 Healthcare 48.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$170M 31.29%
2,000,000
+500,000
+33% +$41.9M
AGN
2
DELISTED
Allergan plc
AGN
$34M 6.27%
+207,871
New +$37.3M
SHPG
3
DELISTED
Shire pic
SHPG
$25.1M 4.63%
161,949
+92,301
+133% +$13.7M
VTRS icon
4
Viatris
VTRS
$19.8B
$19.9M 3.67%
+470,296
New +$18M
MRK icon
5
Merck
MRK
$315B
$19.5M 3.59%
+362,915
New +$20.1M
BMY icon
6
CALL
Bristol-Myers Squibb
BMY
$124B
$18.1M 3.34%
+295,600
New +$18.5M
AZN icon
7
CALL
AstraZeneca
AZN
$263B
$16.2M 2.99%
+233,300
New +$15.7M
ABLX
8
DELISTED
Ablynx NV
ABLX
$15.9M 2.94%
+637,884
New +$14.4M
CLVS
9
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$15.9M 2.92%
233,200
+198,200
+566% +$13.9M
INSM icon
10
Insmed
INSM
$23.1B
$15.6M 2.87%
498,921
+354,921
+246% +$10.5M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$11.3B
$14.6M 2.7%
163,997
+44,336
+37% +$3.86M
DOVA
12
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$13M 2.41%
453,032
+14,913
+3% +$409K
GBT
13
DELISTED
Global Blood Therapeutics, Inc.
GBT
$12.3M 2.26%
311,516
+41,441
+15% +$1.55M
FLXN
14
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
$11.7M 2.15%
+466,500
New +$11.4M
SGMO
15
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$11.6M 2.14%
708,544
-72,456
-9% -$1.08M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$35.6B
$11M 2.02%
86,293
+6,521
+8% +$819K
KYNB
17
Kyntra Bio
KYNB
$29.2M
$9.52M 1.76%
8,034
-659
-8% -$826K
BMRN icon
18
CALL
BioMarin Pharmaceuticals
BMRN
$11.3B
$9.24M 1.7%
+103,600
New +$9.01M
SAGE
19
DELISTED
Sage Therapeutics
SAGE
$9.2M 1.7%
+55,834
New +$5.41M
SCMP
20
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$9.16M 1.69%
+510,486
New +$6.29M
ALXN
21
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$8.66M 1.6%
+72,400
New +$8.82M
CBIO
22
Crescent Biopharma
CBIO
$565M
$8.07M 1.49%
4,804
+1,591
+50% +$2.1M
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.55M 1.39%
231,332
+81,332
+54% +$2.19M
KURA icon
24
Kura Oncology
KURA
$936M
$6.82M 1.26%
445,550
+187,034
+72% +$2.76M
IMMU
25
DELISTED
Immunomedics Inc
IMMU
$6.54M 1.21%
404,528
-387,578
-49% -$4.57M
1
2 3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Nexthera Capital held 60 positions worth $542M, up 40% from $389M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Nexthera Capital deployed $142M of net new capital in Q4 2017, opening 22 new positions and adding to 12 existing holdings. Its largest new stake was Allergan plc: 207,871 shares worth $34M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 50% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $4.57M trimmed.

  • Nexthera Capital's largest Q4 2017 buy was Allergan plc: 207,871 shares worth $34M.
  • Nexthera Capital added most to Shire pic in Q4 2017, an estimated $13.7M increase.
  • Nexthera Capital's biggest Q4 2017 reduction was Immunomedics Inc, cutting an estimated $4.57M.
  • Nexthera Capital fully exited Seagen Inc. Common Stock in Q4 2017, selling an estimated $20.3M.
  • Nexthera Capital's ten largest holdings make up 65% of its $542M portfolio in Q4 2017.
  • Nexthera Capital opened 22 new positions and closed 21 in Q4 2017.
  • Nexthera Capital's portfolio value rose 40% quarter-over-quarter to $542M.

Based on Nexthera Capital's 13F filing for Q4 2017, filed 14 Feb 2018.